With their mild pro-ketogenic properties, sodium-glucose cotransporter 2 inhibitors have been shown to lower the activity of pro-inflammatory pathways, which may constitute an underappreciated aspect of gliflozin therapy in HF [42,43,44]. The gene discussed is SLC5A2; the disease is hydrops fetalis.